Healthcare
Live Price
Offline$4.26
+0.00% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Checkpoint Therapeutics, Inc. (CKPT) is a Healthcare stock with a market cap of $367.72M. The stock last traded around $4.26. Baseline metrics include revenue growth of -60.2%, EPS growth of +48.7%, a dividend yield of 0.0%. What stands out right now is revenue -60.2%, EPS +48.7%, free cash flow +34.6% with operating margin 0.0% and ROIC -245.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CKPT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CKPT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CKPT Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CKPT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.1M
+298.9% YoY
FY Net Income
-$23.1M
+59.2% YoY
Free Cash Flow
-$16.6M
+37.1% YoY
Revenue Growth
-60.2%
EPS Growth
+48.7%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 41K | 103K | 192K | 268K | 1M |
| Gross Profit | 41K | -43M | -50M | -48M | -15M |
| Operating Income | -56M | -52M | -58M | -57M | -23M |
| EBITDA | -56M | -52M | -54M | -56M | -23M |
| Net Income | -56M | -52M | -63M | -57M | -23M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 7M | 5M | 12M | 55M | 41M |
| Total Assets | 7M | 5M | 13M | 56M | 43M |
| Total Liabilities | 20M | 18M | 33M | 26M | 7M |
| Shareholder Equity | -13M | -13M | -19M | 30M | 35M |
| Total Debt | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -7M | -5M | -12M | -55M | -41M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
17M
+37.1% YoY
Capital Expenditures
0
Free Cash Flow
17M
+37.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-2185.9%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.